UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 187

Sortiert nach

Safe de-escalation of chemotherapy in HER2-positive early breast cancer

The Lancet (British edition), 2024-04, Vol.403 (10437), p.1606-1607

Earl, Helena M

2024

Link zum Volltext

Verfügbarkeit prüfen

Spatial and temporal heterogeneity in high-grade serous ovarian cancer: a phylogenetic analysis

PLoS medicine, 2015-02, Vol.12 (2), p.e1001789-e1001789

2015

Link zum Volltext

Verfügbarkeit prüfen

Exploratory Analysis of TP53 Mutations in Circulating Tumour DNA as Biomarkers of Treatment Response for Patients with Relapsed High-Grade Serous Ovarian Carcinoma: A Retrospective Study

PLoS medicine, 2016-12, Vol.13 (12), p.e1002198-e1002198

2016

Link zum Volltext

Verfügbarkeit prüfen

Multi-omic machine learning predictor of breast cancer therapy response

Nature (London), 2022-01, Vol.601 (7894), p.623-629

2022

Link zum Volltext

Verfügbarkeit prüfen

6 versus 12 months of adjuvant trastuzumab for HER2-positive early breast cancer (PERSEPHONE): 4-year disease-free survival results of a randomised phase 3 non-inferiority trial

The Lancet (British edition), 2019-06, Vol.393 (10191), p.2599-2612

2019

Link zum Volltext

Verfügbarkeit prüfen

Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and advanced breast cancer: a proof-of-concept trial

The Lancet (British edition), 2010-07, Vol.376 (9737), p.235-244

2010

Link zum Volltext

Verfügbarkeit prüfen

Comparing Breast Cancer Multiparameter Tests in the OPTIMA Prelim Trial: No Test Is More Equal Than the Others

JNCI : Journal of the National Cancer Institute, 2016-09, Vol.108 (9), p.djw050

2016

Link zum Volltext

Verfügbarkeit prüfen

Effects of the addition of gemcitabine, and paclitaxel-first sequencing, in neoadjuvant sequential epirubicin, cyclophosphamide, and paclitaxel for women with high-risk early breast cancer (Neo-tAnGo): an open-label, 2×2 factorial randomised phase 3 trial

The lancet oncology, 2014-02, Vol.15 (2), p.201-212

2014

Link zum Volltext

Verfügbarkeit prüfen

Saliva samples are a viable alternative to blood samples as a source of DNA for high throughput genotyping

BMC medical genomics, 2012-05, Vol.5 (1), p.19-19, Article 19

2012

Link zum Volltext

Verfügbarkeit prüfen

Randomized Phase II Placebo-Controlled Trial of Maintenance Therapy Using the Oral Triple Angiokinase Inhibitor BIBF 1120 After Chemotherapy for Relapsed Ovarian Cancer

Journal of clinical oncology, 2011-10, Vol.29 (28), p.3798-3804

2011

Link zum Volltext

Verfügbarkeit prüfen

Advanced ovarian cancer: multiparametric MR imaging demonstrates response- and metastasis-specific effects

Radiology, 2012-04, Vol.263 (1), p.149

2012

Link zum Volltext

Verfügbarkeit prüfen

Weekly platinum-based chemotherapy versus 3-weekly platinum-based chemotherapy for newly diagnosed ovarian cancer (ICON8): quality-of-life results of a phase 3, randomised, controlled trial

The lancet oncology, 2020-07, Vol.21 (7), p.969-977

2020

Link zum Volltext

Verfügbarkeit prüfen

Integrative analysis of copy number and gene expression in breast cancer using formalin-fixed paraffin-embedded core biopsy tissue: a feasibility study

BMC genomics, 2017-07, Vol.18 (1), p.526-526, Article 526

2017

Link zum Volltext

Verfügbarkeit prüfen

Replication of Genetic Polymorphisms Reported to Be Associated with Taxane-Related Sensory Neuropathy in Patients with Early Breast Cancer Treated with Paclitaxel

Clinical cancer research, 2014-05, Vol.20 (9), p.2466-2475

2014

Link zum Volltext

Verfügbarkeit prüfen

The Extracellular Matrix Protein TGFBI Induces Microtubule Stabilization and Sensitizes Ovarian Cancers to Paclitaxel

Cancer cell, 2007-12, Vol.12 (6), p.514-527

2007

Link zum Volltext

Verfügbarkeit prüfen

The Relationship between Common Genetic Markers of Breast Cancer Risk and Chemotherapy-Induced Toxicity: A Case-Control Study

PloS one, 2016-07, Vol.11 (7), p.e0158984

2016

Link zum Volltext

Verfügbarkeit prüfen

Reporting of adjuvant breast cancer trials: when is the right time?

Journal of clinical oncology, 2012-01, Vol.30 (1), p.1-2

Earl, Helena M

2012

Link zum Volltext

Verfügbarkeit prüfen

Accelerated versus standard epirubicin followed by cyclophosphamide, methotrexate, and fluorouracil or capecitabine as adjuvant therapy for breast cancer in the randomised UK TACT2 trial (CRUK/05/19): a multicentre, phase 3, open-label, randomised, controlled trial

The lancet oncology, 2017-07, Vol.18 (7), p.929-945

2017

Link zum Volltext

Verfügbarkeit prüfen

Computational pathology of pre-treatment biopsies identifies lymphocyte density as a predictor of response to neoadjuvant chemotherapy in breast cancer

Breast cancer research : BCR, 2016-02, Vol.18 (1), p.21-21, Article 21

2016

Link zum Volltext

Verfügbarkeit prüfen

The PARTNER trial of neoadjuvant olaparib with chemotherapy in triple-negative breast cancer

Nature (London), 2024-05, Vol.629 (8014), p.1142-1148

2024

Link zum Volltext

Verfügbarkeit prüfen

CYP2D6 gene variants: association with breast cancer specific survival in a cohort of breast cancer patients from the United Kingdom treated with adjuvant tamoxifen

Breast cancer research : BCR, 2010-01, Vol.12 (4), p.R64-R64, Article R64

2010

Link zum Volltext

Verfügbarkeit prüfen

1 – 25 von 187

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(180)
Mit Volltextzugriff
(181)

Publikationsform

Sprache

Erscheinungsjahr

n.n

Thema

Humans
(105)
Science & Technology
(99)
Life Sciences & Biomedicine
(90)
Female
(84)
Middle Aged
(58)
Oncology
(55)
Aged
(46)
Breast Cancer
(45)
Adult
(42)
Chemotherapy
(41)
Breast Neoplasms - Drug Therapy
(34)
Antineoplastic Combined Chemotherapy Protocols - Therapeutic Use
(31)
Breast Neoplasms - Pathology
(27)
Medical Research
(24)
Cancer
(23)
Tumors
(23)
Biological And Medical Sciences
(20)
Medical Sciences
(20)
Ovarian Cancer
(19)
Patients
(19)

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

5 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 30 Tagen
(1)
... seit 90 Tagen
(2)

Menü

Weitere Dienste

Einstellungen

Safe de-escalation of chemotherapy in HER2-positive early breast cancer

Spatial and temporal heterogeneity in high-grade serous ovarian cancer: a phylogenetic analysis

Exploratory Analysis of TP53 Mutations in Circulating Tumour DNA as Biomarkers of Treatment Response for Patients with Relapsed High-Grade Serous Ovarian Carcinoma: A Retrospective Study

Multi-omic machine learning predictor of breast cancer therapy response

The somatic mutation profiles of 2,433 breast cancers refines their genomic and transcriptomic landscapes

Weekly dose-dense chemotherapy in first-line epithelial ovarian, fallopian tube, or primary peritoneal carcinoma treatment (ICON8): primary progression free survival analysis results from a GCIG phase 3 randomised controlled trial

6 versus 12 months of adjuvant trastuzumab for HER2-positive early breast cancer (PERSEPHONE): 4-year disease-free survival results of a randomised phase 3 non-inferiority trial

Efficacy of neoadjuvant bevacizumab added to docetaxel followed by fluorouracil, epirubicin, and cyclophosphamide, for women with HER2-negative early breast cancer (ARTemis): an open-label, randomised, phase 3 trial

Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and advanced breast cancer: a proof-of-concept trial

Comparing Breast Cancer Multiparameter Tests in the OPTIMA Prelim Trial: No Test Is More Equal Than the Others

Effects of the addition of gemcitabine, and paclitaxel-first sequencing, in neoadjuvant sequential epirubicin, cyclophosphamide, and paclitaxel for women with high-risk early breast cancer (Neo-tAnGo): an open-label, 2×2 factorial randomised phase 3 trial

Saliva samples are a viable alternative to blood samples as a source of DNA for high throughput genotyping

Randomized Phase II Placebo-Controlled Trial of Maintenance Therapy Using the Oral Triple Angiokinase Inhibitor BIBF 1120 After Chemotherapy for Relapsed Ovarian Cancer

Effects of the addition of gemcitabine, and paclitaxel-first sequencing, in neoadjuvant sequential epirubicin, cyclophosphamide, and paclitaxel for women with high-risk early breast cancer (Neo-tAnGo): an open-label, 2x2 factorial randomised phase 3 trial

Advanced ovarian cancer: multiparametric MR imaging demonstrates response- and metastasis-specific effects

Weekly platinum-based chemotherapy versus 3-weekly platinum-based chemotherapy for newly diagnosed ovarian cancer (ICON8): quality-of-life results of a phase 3, randomised, controlled trial

Integrative analysis of copy number and gene expression in breast cancer using formalin-fixed paraffin-embedded core biopsy tissue: a feasibility study

Replication of Genetic Polymorphisms Reported to Be Associated with Taxane-Related Sensory Neuropathy in Patients with Early Breast Cancer Treated with Paclitaxel

The Extracellular Matrix Protein TGFBI Induces Microtubule Stabilization and Sensitizes Ovarian Cancers to Paclitaxel

The Relationship between Common Genetic Markers of Breast Cancer Risk and Chemotherapy-Induced Toxicity: A Case-Control Study

Reporting of adjuvant breast cancer trials: when is the right time?

Accelerated versus standard epirubicin followed by cyclophosphamide, methotrexate, and fluorouracil or capecitabine as adjuvant therapy for breast cancer in the randomised UK TACT2 trial (CRUK/05/19): a multicentre, phase 3, open-label, randomised, controlled trial

Computational pathology of pre-treatment biopsies identifies lymphocyte density as a predictor of response to neoadjuvant chemotherapy in breast cancer

The PARTNER trial of neoadjuvant olaparib with chemotherapy in triple-negative breast cancer

CYP2D6 gene variants: association with breast cancer specific survival in a cohort of breast cancer patients from the United Kingdom treated with adjuvant tamoxifen

Suchergebnisse filtern